Ranbaxy acquires dermatological and lifestyle product range of Ochoa Labs
GURGAON, India Indian drug maker Ranbaxy announced Thursday that it had acquired the trademarks, marketing rights and product dossiers for the entire dermatological and lifestyle product range of New Delhi-based Ochoa Labs.
Ranbaxy said the products commanded “considerable equity” with doctors, and it will initially market them in India, though it did not name specific products acquired.
“The move strengthens Ranbaxy’s domestic presence and market share in dermatology, a high-growth therapeutic segment for the company,” Ranbaxy chairman and CEO Malvinder Mohan Singh said. “I believe the Indian pharmaceutical space is ripe for consolidation, and Ranbaxy’s intent is to accelerate this trend with a view to reach commanding positions, especially in the high-value chronic and acute therapy areas.”
Pfizer expands generics portfolio with Aurobindo, Claris deals
NEW YORK A big pharmaceutical company has entered licensing agreements with two Indian generics companies, expanding its portfolio by 75 products.
Pfizer announced Wednesday that the agreements, with Aurobindo Pharma and Claris Lifesciences, would “significantly expand” the portfolio of medicines in its Established Products Business Unit, giving it products to market in North America, Europe, Australia, New Zealand and more than 70 emerging market countries.
“[Today’s] announcement demonstrates Pfizer’s commitment to improving the global public health landscape by making needed quality medicines – in a range of disease areas – accessible to underserved populations worldwide,” Pfizer chairman and CEO Jeff Kindler stated. “The off-patent marketplace worldwide too often suffers from quality and supply reliability issues.”
Under the terms of the agreements, Pfizer has acquired the rights to 55 pill drugs and five injected drugs from Aurobindo to sell in emerging markets, and 15 injected drugs from Claris to sell in developed markets.
Lilly, Medtronic to deliver diabetes education
INDIANAPOLIS A drug maker and a medical device maker have announced a collaboration to provide education on care and management of diabetes.
Eli Lilly & Co. and Medtronic said their marketing and sales operations would work with healthcare professionals to deliver diabetes education for patients and caregivers affected by Type 1 diabetes, including the development of educational resources and classes around the initiation and intensive management of insulin, insulin pump therapy and continuous glucose monitoring.
“Medtronic and Lilly are joining together to help improve patient access to high-quality diabetes education,” Medtronic SVP and diabetes business unit president Chris O’Connell said. “Because diabetes management is complicated, it is crucial that physicians and patients have the best access to information and educational resources.”